Menu
Menu
GLP-1 weight loss from a real medical practice in Palm Harbor, not a subscription service. Every prescription is paired with an in-person visit, baseline labs, and ongoing follow-up with your provider.
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone your gut naturally releases after eating. It slows gastric emptying, reduces hunger between meals, and helps regulate blood sugar. The net effect is fewer cravings, smaller portions, and steady weight loss without the white-knuckle willpower that defeats most diets.
The compounded formulation we prescribe is prepared by a licensed US compounding pharmacy and dosed to match the titration schedule used in the landmark STEP clinical trial program. Every vial ships directly to your door once your provider has cleared you, and we bundle the needed syringes and alcohol swabs so there’s nothing for you to source.
You can read our full medical weight loss program overview if you want the bigger picture, or jump to compounded tirzepatide if you’ve already been told you’d be a better fit for the dual-agonist option.
Three steps, one provider, no shortcuts.
A visit at our Palm Harbor clinic to review your history, weight-loss goals, and current medications. We decide together whether semaglutide is the right fit for you.
Baseline labs (A1c, kidney, thyroid, lipid panel) and body composition. Your provider builds a dosing plan and sets realistic milestones for the first 12 weeks.
Check-ins every four weeks for dose titration and side-effect management. Same provider every visit, direct line by text or phone.
Online GLP-1 services sell access to a prescription. They do a questionnaire, ship a vial, and disappear until you want a refill. The problem is that semaglutide is a medication, not a supplement. Thyroid risk, pancreatitis risk, gallbladder changes, and nutritional deficiencies are all real considerations that require labs and follow-up to catch early.
At Olympia Aesthetics & Wellness you see the same provider before you start, during the titration phase, and all the way through maintenance. You have someone who knows your name if you call with a question, and a medical record that reflects what’s actually happening in your body instead of what you checked in a form.
If you’re considering switching from a telehealth provider, bring your last set of labs and a list of your current doses. We’ll build on what you’ve already done rather than restart.
Semaglutide for weight management was studied in the STEP trial program (Semaglutide Treatment Effect in People with Obesity). The flagship trial, STEP 1 (Wilding et al., New England Journal of Medicine, 2021), followed 1,961 adults with obesity for 68 weeks. The average weight loss on 2.4 mg weekly was 14.9% of starting body weight, compared with 2.4% for placebo. About one in three participants lost more than 20% of their body weight.
Cardiovascular benefit was confirmed in SELECT (Lincoff et al., NEJM, 2023), which showed a 20% relative reduction in major adverse cardiovascular events among patients with overweight or obesity and preexisting cardiovascular disease. These findings were the basis for Wegovy’s FDA label update for cardiovascular risk reduction.
Most patients notice appetite change within the first two weeks. Visible weight loss usually begins around week four to six and builds as the dose titrates upward. The slow-and-steady pattern is part of the safety profile, which is why we resist compressing the titration even when patients want faster results.
Week 1–2. Starting dose of 0.25 mg weekly. Most patients feel reduced appetite within days. Some mild nausea or fullness is common; it almost always improves by week three. We send tips on meal timing, hydration, and protein targets.
Week 3–4. Dose increases to 0.5 mg. Appetite suppression is noticeably stronger. Many patients start seeing 2–4 lbs of weight loss per week. We schedule a 15-minute virtual check-in to troubleshoot any side effects.
Week 5–8. Dose advances to 1.0 mg if tolerated. This is where most patients hit their groove. You’re eating smaller portions naturally, not thinking about food between meals, and noticing clothing fit differently.
Week 9–12. Most patients settle into 1.0–1.7 mg as a working dose. We repeat a brief lab panel to confirm kidney and thyroid function remain stable. From here, care is monthly and focused on long-term behavior change plus dose management.
Our program pricing covers the compounded medication, supplies, and your monthly provider follow-up. Baseline labs are billed separately at wholesale cost. Program pricing is typically less than the out-of-pocket cost of brand-name Wegovy when insurance denies coverage, and we quote exact numbers at your consultation once we know your starting dose.
We do not bill insurance directly for compounded medications. We can provide superbills for HSA or FSA reimbursement, and we offer CareCredit for patients who prefer to finance a full 12-month program up front.
In the STEP 1 trial, patients lost an average of 14.9% of their starting body weight over 68 weeks at the full 2.4 mg dose. Real-world results vary with nutrition, activity, and how long you stay on therapy. Most of our patients land in the 10 to 15% range over the first year.
Most people notice reduced appetite within the first two weeks. Visible weight loss usually starts by week four to six and continues steadily as your dose titrates upward. The biggest changes happen between months three and nine.
Nausea, reflux, constipation, and early fullness are the most common, and they are almost always dose-related. They tend to improve after the first few weeks. We titrate slowly to minimize them, and we have a detailed toolkit for managing each one.
Rarely, GLP-1 therapy can trigger pancreatitis, gallbladder disease, or worsen preexisting gastroparesis. We screen for these risks at your initial visit and teach you the symptoms to report. Your labs catch most issues before they become problems.
The active ingredient is identical. Ozempic (diabetes) and Wegovy (weight loss) are brand-name products made by Novo Nordisk. Our compounded version is prepared by a licensed US 503A or 503B compounding pharmacy and is typically significantly more affordable.
The monthly program includes the compounded medication, supplies, and your monthly provider follow-up. Pricing depends on your dose and is typically meaningfully less than the out-of-pocket cost of brand-name GLP-1s. Baseline labs are billed at wholesale. We give you exact numbers at the consultation.
Many patients taper to a maintenance dose once they hit their target. Stopping abruptly often leads to appetite returning and weight regain within three to six months, so we wean down gradually under supervision.
In most cases yes, but we review your full medication list at the consult. There are specific interactions (oral contraceptives, certain diabetes meds, thyroid replacement) that we account for. If you’re on insulin or sulfonylureas, dosing needs a careful adjustment.
A plateau around month six is not unusual. We troubleshoot nutrition, activity, and dose first. If you’ve plateaued despite optimization, we may switch you to compounded tirzepatide, which works on a second receptor pathway.
Oliver Morris, DO is the prescribing physician. You’ll meet him at your first visit and see him for follow-up throughout your program. Read his full bio on the Oliver Morris, DO page.
If you’re a candidate, we’ll build your plan at the first visit and start labs the same day. Free initial phone consultation available.
Enter your email address below to receive our newsletter for events and specials!
Contact information is for the sole use of
Olympia Aesthetics & Wellness and will not be redistributed.
10 am – 6 pm Monday
10 am – 6 pm Tuesday
10 am – 6 pm Wednesday
10 am – 6 pm Thursday
10 am – 6 pm Friday
10 am – 2 pm Saturday
10 am – 2 pm Sunday
Accessibility: Olympia Aesthetics & Wellness is committed to ensuring our website is accessible to all users. If you experience any difficulty, please contact us at (727) 274 – 1972 or [email protected]. Click for more details